{"id":"ciclesonide-nasal","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Epistaxis (nosebleed)"},{"rate":null,"effect":"Nasal irritation"},{"rate":null,"effect":"Pharyngitis"}]},"_chembl":{"chemblId":"CHEMBL2040682","moleculeType":"Small molecule","molecularWeight":"540.70"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ciclesonide is a prodrug that is converted to its active metabolite in the nasal tissue, where it binds to glucocorticoid receptors in the cytoplasm. This binding translocates the receptor to the nucleus, where it modulates gene transcription to decrease production of inflammatory cytokines, chemokines, and adhesion molecules. The result is reduced nasal inflammation, congestion, and allergic symptoms.","oneSentence":"Ciclesonide is an inhaled corticosteroid that reduces inflammation in the nasal airways by binding to glucocorticoid receptors and suppressing inflammatory mediator production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:30:00.581Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Allergic rhinitis"},{"name":"Nasal polyps (off-label use)"}]},"trialDetails":[{"nctId":"NCT04870333","phase":"PHASE2, PHASE3","title":"PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V","status":"COMPLETED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2021-02-19","conditions":"Covid19","enrollment":2240},{"nctId":"NCT00458835","phase":"PHASE4","title":"Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)","status":"COMPLETED","sponsor":"Covis Pharma S.à.r.l.","startDate":"2007-04","conditions":"Allergic Rhinitis","enrollment":30},{"nctId":"NCT04435795","phase":"PHASE2, PHASE3","title":"Inhaled Ciclesonide for Outpatients With COVID19","status":"TERMINATED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2020-09-15","conditions":"COVID 19","enrollment":215},{"nctId":"NCT01550471","phase":"PHASE4","title":"Sunovion Growth Study Pediatric Subjects With Mild Asthma & Allergic Rhinitis","status":"COMPLETED","sponsor":"West Penn Allegheny Health System","startDate":"2012-03","conditions":"Asthma, Allergic Rhinitis","enrollment":22},{"nctId":"NCT02665754","phase":"PHASE1","title":"Intralymphatic Immunotherapy for House Dust Mite, Dog, and Cat Allergy Using Tyrosine S® in Allergic Rhinitis","status":"COMPLETED","sponsor":"Gachon University Gil Medical Center","startDate":"2016-07","conditions":"Allergic Rhinitis","enrollment":32},{"nctId":"NCT02155881","phase":"PHASE3","title":"Efficacy and Safety of Ciclesonide Nasal Spray in Participants With Seasonal Allergic Rhinitis (SAR) in Russia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-08","conditions":"Seasonal Allergic Rhinitis","enrollment":80},{"nctId":"NCT01369563","phase":"","title":"Efficacy, Safety & Tolerability of Ciclesonide 200mcg Spray 4 Weeks Treatment for Intermittent & Persistent Rhinitis","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-08","conditions":"Perennial Rhinitis, Seasonal Rhinitis","enrollment":1630},{"nctId":"NCT00163488","phase":"PHASE3","title":"Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With Perennial Allergic Rhinitis (BY9010/M1-409)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-01","conditions":"Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever","enrollment":106},{"nctId":"NCT00807053","phase":"PHASE2","title":"Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR) (BY9010/M1-602)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-04","conditions":"Rhinitis, Allergic, Seasonal","enrollment":480},{"nctId":"NCT00659594","phase":"PHASE3","title":"Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in Treatment of Seasonal Allergic Rhinitis (BY9010/M1-406)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-11","conditions":"Rhinitis, Allergic, Seasonal, Hay Fever","enrollment":500},{"nctId":"NCT00659750","phase":"PHASE3","title":"To Assess the Safety and Efficacy of Ciclesonide Applied as a Nasal Spray in the Treatment of Perennial Allergic Rhinitis (BY9010/M1-402)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-12","conditions":"Rhinitis, Allergic, Perennial","enrollment":418},{"nctId":"NCT00659841","phase":"PHASE3","title":"To Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-401)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-12","conditions":"Rhinitis, Allergic, Seasonal, Hay Fever","enrollment":302},{"nctId":"NCT00659503","phase":"PHASE3","title":"Study Using the Environmental Exposure Unit (EEU) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-407)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-02","conditions":"Rhinitis, Allergic, Seasonal, Hay Fever","enrollment":420},{"nctId":"NCT00658918","phase":"PHASE3","title":"To Assess the Safety of Ciclesonide, Applied as a Nasal Spray at Three Dose Levels, in the Treatment of Perennial Allergic Rhinitis in Pediatrics (BY9010/M1-405)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-09","conditions":"Rhinitis, Allergic, Perennial, Hay Fever","enrollment":120},{"nctId":"NCT00163514","phase":"PHASE3","title":"Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010/M1-403)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-05","conditions":"Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever","enrollment":636},{"nctId":"NCT00659048","phase":"PHASE3","title":"Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Beclomethasone Dipropionate (HFA-BDP) in Patients With Perennial Allergic Rhinitis (PAR) (BY9010/M1-408)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-12","conditions":"Rhinitis, Allergic, Perennial","enrollment":106},{"nctId":"NCT00305487","phase":"PHASE3","title":"Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-03","conditions":"Hay Fever, Seasonal Allergic Rhinitis","enrollment":660},{"nctId":"NCT00261287","phase":"PHASE3","title":"Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-11","conditions":"Hay Fever, Perennial Allergic Rhinitis","enrollment":102},{"nctId":"NCT00384475","phase":"PHASE3","title":"A Study of Ciclesonide Nasal Spray in Patients 18 Years and Older With Seasonal Allergic Rhinitis (BY9010/M1-413)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-10","conditions":"Rhinitis, Allergic, Seasonal, Hay Fever","enrollment":500},{"nctId":"NCT00163501","phase":"PHASE3","title":"Safety and Effectiveness of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis During One Year Treatment (BY9010/M1-404)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-12","conditions":"Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever","enrollment":600},{"nctId":"NCT00806754","phase":"PHASE4","title":"Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy (BY9010/M1-490)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-11","conditions":"Rhinitis, Allergic, Perennial","enrollment":340},{"nctId":"NCT00790023","phase":"PHASE3","title":"Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-11","conditions":"Seasonal Allergic Rhinitis","enrollment":707},{"nctId":"NCT02665806","phase":"PHASE3","title":"Ciclesonide vs Fluticasone Nasal Sprays in Nasal Poplyposis","status":"UNKNOWN","sponsor":"Tehran University of Medical Sciences","startDate":"2016-01","conditions":"Chronic Rhinosinustis With Polyps","enrollment":32},{"nctId":"NCT02273817","phase":"PHASE3","title":"A Study Comparing The Bioequivalence Of Ciclesonide Nasal Spray (Apotex, Inc.) To That Of Omnaris™ Nasal Spray (Sepracor, Inc.) In The Treatment Of Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"Apotex Inc.","startDate":"2011-03","conditions":"Seasonal Allergic Rhinitis","enrollment":580},{"nctId":"NCT01654536","phase":"PHASE4","title":"A 6 Month Safety Study Of Ciclesonide Nasal Aerosol (Zetonna®) And Ciclesonide Nasal Spray (Omnaris®) In Subjects 12 Years And Older With Perennial Allergic Rhinitis (PAR)","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2012-09","conditions":"Perennial Allergic Rhinitis","enrollment":737},{"nctId":"NCT01378429","phase":"PHASE3","title":"Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2011-07","conditions":"Perennial Allergic Rhinitis, PAR","enrollment":89},{"nctId":"NCT01458275","phase":"PHASE3","title":"A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR)","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2011-11","conditions":"Seasonal Allergic Rhinitis","enrollment":847},{"nctId":"NCT01451541","phase":"PHASE3","title":"A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2011-10","conditions":"Perennial Allergic Rhinitis, PAR","enrollment":848},{"nctId":"NCT00793858","phase":"PHASE4","title":"A Pilot Investigation of Ciclesonide When Administered as a Hypotonic Versus an Isotonic Formulation of Ciclesonide Nasal Spray","status":"WITHDRAWN","sponsor":"University of Chicago","startDate":"2009-02","conditions":"Allergic Rhinitis","enrollment":""},{"nctId":"NCT01401465","phase":"PHASE3","title":"Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal Spray","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2011-07","conditions":"Perennial Allergic Rhinitis","enrollment":327},{"nctId":"NCT01287364","phase":"PHASE3","title":"Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2011-02","conditions":"Perennial Allergic Rhinitis","enrollment":185},{"nctId":"NCT01371786","phase":"PHASE1","title":"A Phase 1 Scintigraphy Study to Assess Nasal Deposition of Ciclesonide. Using a Novel Nasal Metered Dose Inhaler","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2011-06","conditions":"Allergic Rhinitis (AR)","enrollment":14},{"nctId":"NCT01430260","phase":"PHASE4","title":"Omnaris Versus Levocetirizine Phase 4 Study","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2011-01","conditions":"Allergic Rhinitis","enrollment":349},{"nctId":"NCT01033825","phase":"PHASE3","title":"Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2010-01","conditions":"Perennial Allergic Rhinitis","enrollment":310},{"nctId":"NCT01067105","phase":"PHASE3","title":"A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2010-02","conditions":"Perennial Allergic Rhinitis","enrollment":824},{"nctId":"NCT00953147","phase":"PHASE3","title":"A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2009-08","conditions":"Allergic Rhinitis, Perennial Allergic Rhinitis","enrollment":1110},{"nctId":"NCT01010971","phase":"PHASE3","title":"Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2009-12","conditions":"Seasonal Allergic Rhinitis","enrollment":671}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"VOMITING"},{"count":1,"reaction":"AORTIC DISSECTION"},{"count":1,"reaction":"ARTHRALGIA"},{"count":1,"reaction":"BLOOD PRESSURE INCREASED"},{"count":1,"reaction":"BONE INFARCTION"},{"count":1,"reaction":"CONDITION AGGRAVATED"},{"count":1,"reaction":"DEHYDRATION"},{"count":1,"reaction":"DIARRHOEA"},{"count":1,"reaction":"DIZZINESS"},{"count":1,"reaction":"DRUG EFFECT DECREASED"}],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Omnaris"],"phase":"marketed","status":"active","brandName":"Ciclesonide nasal","genericName":"Ciclesonide nasal","companyName":"McGill University Health Centre/Research Institute of the McGill University Health Centre","companyId":"mcgill-university-health-centre-research-institute-of-the-mcgill-university-heal","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ciclesonide is an inhaled corticosteroid that reduces inflammation in the nasal airways by binding to glucocorticoid receptors and suppressing inflammatory mediator production. Used for Allergic rhinitis, Nasal polyps (off-label use).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}